SCHEMBL952362

SCHEMBL952362

N#Cc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
TSHR P16473 4/20 0.41
CYP3A4 P08684 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RECQL P46063 1/20 0.41
GPR35 Q9HC97 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
KDM4E B2RXH2 2/20 0.37
AHR P35869 1/20 0.36
MAP2K1 Q02750 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28338346 0.85 GPR35 (0.42) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL28031894 0.85 ALDH1A1 (0.38) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL2947899 0.83 ALDH1A1 (0.36) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL15129217 0.83 TRPV4 (0.46) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL8968834 0.83 GSK3A (0.40) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL967389 0.83 KDM4E (0.47) ALDH1A1TSHRCYP3A4HPGDHSD17B10
SCHEMBL15850516 0.80 VCAM1 (0.40) ALDH1A1TSHRCYP3A4HPGDTP53
SCHEMBL1900659 0.78 CYP3A4 (0.50) ALDH1A1CYP3A4HPGDHSD17B10TP53
SCHEMBL21305046 0.78 ALDH1A1 (0.38) ALDH1A1CYP3A4HPGDTP53MEN1
SCHEMBL21064821 0.78 TRPV4 (0.41) ALDH1A1CYP3A4HPGDHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111499540-B Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method 中南民族大学 2022-09-27 CN claimed
CN-113024412-A Preparation method of 2,4, 6-trichlorobenzonitrile 上海立科化学科技有限公司 2021-06-25 CN claimed
CN-111499540-A Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method 中南民族大学 2020-08-07 CN claimed
JP-60023358-A None JP disclosed
US-20250242338-A1 IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME OSAKA UNIVERSITY (JP) 2025-07-31 US disclosed
EP-4509462-A1 IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME OSAKA UNIVERSITY (JP) 2025-02-19 EP disclosed
WO-2023200015-A1 IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME 国立大学法人大阪大学 2023-10-19 WO disclosed
CN-111499540-B Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method 中南民族大学 2022-09-27 CN disclosed
CN-111499540-B Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method 中南民族大学 2022-09-27 CN disclosed
CN-111499540-B Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method 中南民族大学 2022-09-27 CN disclosed
CN-111004149-B Method for preparing polyfluorobenzonitrile by catalytic fluorination of polychlorinated benzonitrile 大连奇凯医药科技有限公司 2022-06-07 CN disclosed
EP-1015402-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES Aventis Research & Technologies GmbH & Co. KG (DE) 2000-07-05 EP disclosed
WO-1999011588-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-03-11 WO disclosed
US-5795905-A 3-AMINO-5-PHENYL-1,2,4-TRIAZOLES NEUROCRINE BIOSCIENCES, INC. (US) 1998-08-18 US disclosed
EP-0846108-A1 AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 1998-06-10 EP disclosed
WO-1996039400-A1 AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 1996-12-12 WO disclosed
EP-0141228-B1 A PROCESS FOR PRODUCING POLYCHLOROBENZONITRILE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1988-01-07 EP disclosed
US-4530797-A Ammoxidation of toluene derivative having chlorine in positions 2 and 6 in presence of catalyst NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1985-07-23 US disclosed
EP-0141228-A1 A process for producing polychlorobenzonitrile NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1985-05-15 EP disclosed
JP-S6023358-A 2,4,6-TRIFLUOROBENZONITRILE ISHIHARA SANGYO KAISHA LTD 1985-02-05 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242338-A1 IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME FECH, PI4K2A, PHOSPHO1 ALDH1A1 4269/4885TSHR 2770/4885CYP3A4 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.